|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Product sales | |||||
| Non-cash royalty revenue related to the sales of future royalties | |||||
| License, collaboration and other revenue | |||||
| Total revenue | |||||
| Operating costs and expenses: | |||||
| Cost of goods sold | |||||
| Research and development (including $2,636 and $277 for the year ended December 31, 2025 and 2024, respectively, from a related party) | |||||
| General and administrative | |||||
| Restructuring and impairment | |||||
| Impairment of goodwill | |||||
| Gain on sale of the Huntsville manufacturing facility | |||||
| Total operating costs and expenses | |||||
| Loss from operations | |||||
| Non-operating income (expense): | |||||
| Change in fair value of development derivative liability | |||||
| Non-cash interest expense on liabilities related to the sales of future royalties | |||||
| Loss on revaluation of liability related to the sale of future royalties | |||||
| Interest income | |||||
| Other income (expense), net (including $1,110 and $0 for the year ended December 31, 2025 and 2024, respectively, from a related party) | |||||
| Total non-operating income (expense), net | |||||
| Loss before provision for income taxes | |||||
| Loss before benefit for income taxes and equity method investment | |||||
| Benefit for income taxes | |||||
| Loss before equity method investment | |||||
| Loss from equity method investment | |||||
| Net loss | |||||
| Basic net loss per share (in dollars per share) | |||||
| Diluted net loss per share (in dollars per share) | |||||
| Weighted average shares outstanding used in computing basic net loss per share (in shares) | |||||
| Weighted average shares outstanding used in computing diluted net loss per share (in shares) | |||||
Loading...
